No Major Catalyst, Wells Fargo Downgraded Vertex

GuruFocus.com

01-31

January 31, 2025 Wells Fargo analyst Mohit Bansal was not excited by the upcoming launches of Vertex Pharmaceutical (NASDAQ:VRTX)'s drugs, Alyftrek and Suzetrigine. So, the analyst downgraded Vertex from Overweight to Equal-Weight and lowering the target price to $460, which was reached today.

Bansal saw no major catalyst could drive the stock up in the near future, he also mentioned that Vertex might need to add more pipelines to its drug portfolio to drive growth.

Warning! GuruFocus has detected 5 Warning Signs with VRTX.

According to the consensus that consist of 29 analysts, the target price for Vertex is ranged from $325.00 to $591.00 with the average of $495.25. GuruFocus estimates the value for Vertex is $434.37, suggesting a downside from current price of $460.64.

This article first appeared on GuruFocus.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2508962338"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2508962338\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2508962338?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-31 23:59","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2508962338","market":"us","top_or_hot":-1,"title":"No Major Catalyst, Wells Fargo Downgraded Vertex","media":"GuruFocus.com","content":"<html><body><p>January 31, 2025 Wells Fargo analyst Mohit Bansal was not excited by the upcoming launches of Vertex Pharmaceutical (NASDAQ:VRTX)'s drugs, Alyftrek and Suzetrigine. So, the analyst downgraded Vertex from Overweight to Equal-Weight and lowering the target price to $460, which was reached today. </p>\n<p>Bansal saw no major catalyst could drive the stock up in the near future, he also mentioned that Vertex might need to add more pipelines to its drug portfolio to drive growth. </p>\n<ul>\n<li>Warning! GuruFocus has detected 5 Warning Signs with VRTX.</li>\n</ul>\n<p><img height=\"400\" src=\"https://s1.yimg.com/uu/api/res/1.2/_wzJgVrNsuT4DLCGkCJ36A--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/us.finance.gurufocus/79a58c531d3fdbe5f23c48950fb3e6c7\" width=\"550\"/></p>\n<p>According to the consensus that consist of 29 analysts, the target price for Vertex is ranged from $325.00 to $591.00 with the average of $495.25. GuruFocus estimates the value for Vertex is $434.37, suggesting a downside from current price of $460.64.</p>This article first appeared on \nGuruFocus.\n<br/></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>No Major Catalyst, Wells Fargo Downgraded Vertex</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNo Major Catalyst, Wells Fargo Downgraded Vertex\n</h2>\n<h4 class=\"meta\">\n</h4><p class=\"head\">\n<strong class=\"h-name small\">GuruFocus.com</strong><span class=\"h-time small\">2025-01-31 23:59</span>\n</p>\n</header>\n<article>\n<p>January 31, 2025 Wells Fargo analyst Mohit Bansal was not excited by the upcoming launches of Vertex Pharmaceutical (NASDAQ:VRTX)'s drugs, Alyftrek and Suzetrigine. So, the analyst downgraded Vertex from Overweight to Equal-Weight and lowering the target price to $460, which was reached today. </p>\n<p>Bansal saw no major catalyst could drive the stock up in the near future, he also mentioned that Vertex might need to add more pipelines to its drug portfolio to drive growth. </p>\n<ul>\n<li>Warning! GuruFocus has detected 5 Warning Signs with VRTX.</li>\n</ul>\n<p><img height=\"400\" src=\"https://s1.yimg.com/uu/api/res/1.2/_wzJgVrNsuT4DLCGkCJ36A--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/us.finance.gurufocus/79a58c531d3fdbe5f23c48950fb3e6c7\" width=\"550\"/></p>\n<p>According to the consensus that consist of 29 analysts, the target price for Vertex is ranged from $325.00 to $591.00 with the average of $495.25. GuruFocus estimates the value for Vertex is $434.37, suggesting a downside from current price of $460.64.</p>This article first appeared on \nGuruFocus.\n<br/>\n<div class=\"bt-text\">\n<p> 來源：<a href=\"https://finance.yahoo.com/news/no-major-catalyst-wells-fargo-155955683.html\">GuruFocus.com</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VRTX","symbol_name":"福泰製藥","start_time":0,"source_url":"https://finance.yahoo.com/news/no-major-catalyst-wells-fargo-155955683.html","article_id":"2508962338","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2508962338","pubTimestamp":1738339195,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"January 31, 2025 Wells Fargo analyst Mohit Bansal was not excited by the upcoming launches of Vertex Pharmaceutical 's drugs, Alyftrek and Suzetrigine. So, the analyst downgraded Vertex from Overweight to Equal-Weight and lowering the target price to $460, which was reached today.Bansal saw no major catalyst could drive the stock up in the near future, he also mentioned that Vertex might need to add more pipelines to its drug portfolio to drive growth.GuruFocus has detected 5 Warning Signs with VRTX.According to the consensus that consist of 29 analysts, the target price for Vertex is ranged from $325.00 to $591.00 with the average of $495.25. GuruFocus estimates the value for Vertex is $434.37, suggesting a downside from current price of $460.64.This article first appeared on","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"VRTX":"福泰制药","VERX":"Vertex, Inc.","VTNR":"顶点能源"},"translate_title":"没有主要催化剂，富国银行下调Vertex评级","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VERX":1,"VRTX":1,"VTNR":1},"content_text":"January 31, 2025 Wells Fargo analyst Mohit Bansal was not excited by the upcoming launches of Vertex Pharmaceutical (NASDAQ:VRTX)'s drugs, Alyftrek and Suzetrigine. So, the analyst downgraded Vertex from Overweight to Equal-Weight and lowering the target price to $460, which was reached today. \nBansal saw no major catalyst could drive the stock up in the near future, he also mentioned that Vertex might need to add more pipelines to its drug portfolio to drive growth. \n\nWarning! GuruFocus has detected 5 Warning Signs with VRTX.\n\n\nAccording to the consensus that consist of 29 analysts, the target price for Vertex is ranged from $325.00 to $591.00 with the average of $495.25. GuruFocus estimates the value for Vertex is $434.37, suggesting a downside from current price of $460.64.This article first appeared on \nGuruFocus.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}